Dec
3
2026
Upcoming webinar

Smarter bioprocessing: using AI to bridge process design and manufacturing scale-up

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Smarter bioprocessing: using AI to bridge process design and manufacturing scale-up

Join two vaccine CMC experts for a fireside chat on where AI is delivering results in vaccine process development and manufacturing. The discussion will focus on predictive process modeling, including digital twins and data-driven process control, and on how AI can reduce risk when moving a process into commercial-scale manufacturing.

Attendees will gain a practical view of how these tools link process design to scale-up, and where they are ready for use in vaccine programs.

Attend this fireside chat to:

  • Understand how predictive process models, including digital twins, can inform process design decisions before scale-up.
  • Learn how data-driven process control is being applied to improve consistency in vaccine bioprocessing.
  • Explore how AI and data approaches can de-risk tech transfer from development into commercial-scale manufacturing.
  • Gain a grounded view of where AI is delivering in practice, to help prioritize where to focus investment in your own programs.
Ravi Ganapathy, PhD, PGDBA
Ravi Ganapathy, PhD, PGDBA
Senior Director, Vaccine Process Development at International Vaccine Institute (IVI), Seoul, South Korea

Dr Ravi Ganapathy is Senior Director of Vaccine Process Development at the International Vaccine Institute (IVI), Seoul, South Korea. He has over 33 years of experience in biotech industry, including over 29 years in vaccines across India, South Korea and Singapore. He previously held senior roles at Hilleman Laboratories, Biological E., Shantha Biotechnics (a Sanofi company) and Bharat Biotech. He has developed and manufactured recombinant, bacterial, conjugate and viral vaccines, with expertise in technology transfer, facility set-up and GMP compliance. He played a key role in developing and securing regulatory approval for India’s first cell culture-derived pandemic H1N1 influenza vaccine.

Renske Hesselink, PhD
Renske Hesselink, PhD
Director, PDM Innovations at CEPI

Dr Renske Hesselink is a biochemist with a background in the vaccine industry, who is currently working as Director PDM Innovations at CEPI, the Coalition for Epidemic Preparedness Innovations. At CEPI, she works on technology innovations that enable the rapid development and suitably scaled manufacturing of equitably accessible vaccines for outbreak response. Such innovations are instrumental for CEPI’s 100 Days Mission, to prevent future pandemics by developing safe and effective vaccines against the next Disease X within 100 days.

Prior to joining CEPI, Renske worked in the pharmaceutical industry for over 10 years, mainly in formulation, analytical, and drug product development for various vaccines and biologics. She contributed to the Ebola vaccine developed by Janssen during the outbreak in West-Africa, scaling up the process and making vaccine doses available as soon as possible for clinical trials and containment of the epidemic. She also worked on the stabilization of protein- and viral vector-based vaccines against e.g. RSV and HIV. Renske holds an MSc degree in Molecular Sciences from Wageningen University, the Netherlands, and a PhD in Membrane Biology from the University of Leeds, UK.